-
Jan 09 |
Diagnostics World News | There can be little debate that Alzheimer’s disease is one of the greatest healthcare challenges we face globally. Most recent estimates suggest that over 57 million people worldwide are living with dementia, of which 70% is caused by Alzheimer’s. With aging societies, this number is expected to increase to over 150 million by 2050. Yet there is a growing sense of impending change, particularly because the way we diagnose Alzheimer’s is now at a pivotal moment.
More
-
Jan 08 |
Diagnostics World News | In just a few years, the monitoring of brain signals via ubiquitous earbuds will be as common as heart rhythm tracking by popular smartwatch brands like Apple and Fitbit. People wearing these next-generation earbuds will have their electroencephalogram (EEG) effortlessly analyzed while they listen to music or make phone calls.
More
-
Jan 07 |
Diagnostics World News | After less than three years of collecting voice samples from individuals with amyotrophic lateral sclerosis, and a control group of healthy volunteers, the Peter Cohen Foundation awaits approval from the Food and Drug Administration of its algorithm as a secondary biomarker for tracking the progression of the devastating neurological disease. The drug development tool, a “listener effort” prediction model, will be used in a multitude of clinical trials as soon as the first quarter of 2026.
More
-
Jan 06 |
Diagnostics World News | To kick off 2026, we spoke with industry experts and leaders in the Diagnostics World community about what they expect and look forward to in the new year. Here are the full trends and predictions, including more on AI, data management and collection, precision diagnostics, new testing, and more.
More
-
Dec 29 |
Diagnostics World News | Diagnostics is gaining growing traction within several companies not historically diagnostics-focused, and it is the subject of a fair amount of AI investment as well. NVIDIA’s partnerships with diagnostics companies came up in more than one top story of the year, and AI’s role for image processing came up in others. Even earlier multi-cancer early detection tests were notable and the growing trend in women’s health was reflected in attention to endometriosis diagnosis.
More
-
Dec 23 |
Diagnostics World News | Circular Genomics will accelerate the clinical development and commercialization of their circRNA biomarker platform for the early detection of Alzheimer's disease; Wearlinq introduces eWave, the first continuous, multi-lead (6-lead) ECG in a small, wireless form factor; Subsense is building a bidirectional BCI platform designed to record and modulate brain activity without surgical implants; and more.
More
-
Dec 22 |
Diagnostics World News | The Singapore-MIT Alliance for Research and Technology launches a new collaborative research project; Cleveland Diagnostics receives FDA approval of their IsoPSA in vitro diagnostic kit; Roche announces that its first point-of-care test for the detection of Bordetella infections has been granted FDA 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 waiver; and more.
More
-
Dec 18 |
Diagnostics World News | Researchers have identified a previously overlooked mechanism controlling allergic reactions in the gut, potentially paving the way for novel treatments for conditions ranging from food allergies to irritable bowel syndrome.
More
-
Dec 16 |
Diagnostics World News | Good sleep patterns impact many aspects of the broader health status of individuals, but the measurement of slumber quality tends to fall at the extremes of either simplistic sleep logs or cumbersome in-patient sleep studies, or polysomnography. A new sleep-staging framework driven by artificial intelligence and an associated Apple Watch app known as BIDSleep is designed to bridge that gap by turning a smartwatch into a sleep-staging device that can distinguish between light, deep, and rapid eye movement sleep.
More
-
Dec 11 |
Diagnostics World News | Illumina today announced an investment and collaboration into MyOme, a genomics and risk modeling company. The collaboration and investment will help advance MyOme’s Proactive Health (MPH) Trial—a clinical trial seeking to quantify the cost savings and improved patient outcomes for whole-genome sequencing (WGS) combined with MyOme’s AI-integrated risk models (IRMs)—and help expand MyOme’s suite of proactive health and rare disease diagnostic tests. Neither financial details nor milestones of the investment were disclosed.
More
-
Jan 08 |
More
-
Jan 07 |
PharmaForceIQ has announced its acquisition of Aktana, aligning its cutting-edge digital orchestration platform with the industry’s premier AI-driven field Next-Best-Action (NBA) platform.
More
-
Dec 17 |
The first START site in New York launches a new strategic partnership to provide cutting-edge cancer research.
More
-
Dec 15 |
Built directly into the elluminate ecosystem, the agents combine governed data with explainable intelligence to accelerate decisions
More
-
Dec 15 |
CluePoints, provider of leading statistical and AI-driven software solutions, has won the ‘Best Contract Research Organization– Specialist Providers’ category at the 2025 Scrip Awards.
More
-
Dec 11 |
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. Using AMD EPYC™ CPUs on Oracle Cloud Infrastructure (OCI), 4D Path’s QPOR™ platform—a physics-informed, AI-driven, deterministic software engine—can convert routine biopsy images into interpretable biomarkers of tumor and immune response faster and at lower cost.
More
-
Dec 10 |
New York Gastroenterology Associates, LLP (NYGA), New York City’s leading independent gastroenterology practice, is working with Proscia, a pathology AI company, to advance its standard of excellence
More
-
Dec 10 |
New Scale Technologies is announcing the availability of the new DART linear actuator and stage platform.
The DART line is designed to meet the needs of photonic instruments and life science companies looking for smart motion solutions with longer travel and lower cost for high-volume applications. The DART Smart Linear Actuator builds on New Scale’s proprietary SQUIGGLE® technology, offering a greater range of motion and higher force.
More
-
Dec 04 |
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced that the company’s Q-Plasia OncoReader (QPOR™) platform has successfully predicted treatment response in patients with early-stage triple-negative breast cancer (TNBC) using digitized baseline biopsy images. Analysis conducted within the Translational Breast Cancer Research Consortium (TBCRC) 030 clinical trial represents the first demonstration of a statistical physics and tumor biology-based computational biomarker predicting post-treatment outcomes from pre-treatment tissue alone, without any clinical or molecular inputs.
More
-
Dec 03 |
Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale
More
View more articles